Samsung Biologics

삼성바이오로직스 · 207940

Health Care Pharmaceuticals · KOSPI

Large-cap

Market cap US$45.9B (₩63.3T)

Overview

Samsung Biologics is a contract manufacturer of biologic medicines, meaning it produces drugs on behalf of pharmaceutical and biotech companies rather than marketing its own branded therapies.

It runs large-scale facilities that make antibody and other protein-based treatments under contract, and it also offers drug-development support services. Global drugmakers use its capacity to scale up production. The company is part of South Korea's Samsung group.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$3.3B

▲ +0.2% YoY

Operating profit · FY2025

US$1.5B

▲ +56.8% YoY

Net income · FY2025

US$1.3B

▲ +64.7% YoY

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$2.7B(₩3.7T)	US$3.3B(₩4.5T)	US$3.3B(₩4.6T)
Operating profit	US$807M(₩1.1T)	US$956.6M(₩1.3T)	US$1.5B(₩2.1T)
Net income	US$621.5M(₩857.7B)	US$785M(₩1.1T)	US$1.3B(₩1.8T)

Revenue

FY2023US$2.7B
FY2024US$3.3B
FY2025US$3.3B

Operating profit

FY2023US$807M
FY2024US$956.6M
FY2025US$1.5B

Net income

FY2023US$621.5M
FY2024US$785M
FY2025US$1.3B

Key ratios (FY2025)

ROE

23.9%

Debt/Eq

48.4%

Op. margin

45.4%

Net margin

39.2%

Rev. YoY

▲ +0.2%

Why it matters

It belongs to the Samsung group and is one of several Samsung affiliates active in healthcare and biotechnology.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?